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Abstract
Genetic diversity and antiviral activity for five common antiviral drugs of echovirus (ECV) 5 isolated in Korea have
been described. The present study extended these tests to a Korean ECV 18 isolate. An outbreak of aseptic
meningitis caused by the ECV 18 isolate was reported in Korea in 2005, marking the first time this virus had been
identified in the country since enterovirus surveillance began in 1993. Using a sample isolated from stool specimen
of a 5-year-old male patient with aseptic meningitis, the complete genome sequence was obtained and was
compared it with the Metcalf prototype strain. Unlike the ECV5 isolate, the 3’ untranslated region had the highest
identity value (94.2%) at the nucleotide level, while, at the amino acid level, the P2 region displayed the highest
identity value (96.9%). These two strains shared all cleavage sites, with the exception of the 2B/2C site, which was
RQ/NN in the Metcalf strain but RQ/NS in the Korean ECV 18 isolate. In Vero cells infected with the Korean ECV 18
isolate, no cytotoxicity was observed in the presence of azidothymidine, acyclovir, amantadine, lamivudine, or
ribavirin, when the drugs were administered at a CC50 value >100 μg/mL. Of the five drugs, only amantadine (IC50:
4.97 ± 0.77 μg/mL, TI: 20.12) and ribavirin (IC50: 7.63 ± 0.87 μg/mL, TI: 13.11) had any antiviral activity against the
Korean ECV 18 isolate in the five antiviral drugs. These antiviral activity effects were similar with results of the
Korean ECV5 isolate.
Introduction
Human enteroviruses (HEVs), RNA viruses from the
Picornaviridae family, comprise more than 80 immuno-
logically-distinct serotypes that cause infections in
humans. HEVs can be grouped as HEV-A to HEV-D
and polioviruses. The HEV-B group containing echo-
virus (ECV) 18 consists coxsackieviruses B (CVB) 1 to 6,
coxsackievirus A9, ECV 1 to ECV 7, ECV 9, ECV 11 to
ECV 21, ECV 24 to ECV 27, ECV 29 to 33, enterovirus
(EV) 69, and EV 73 [1-4].
ECVs cause the same types of infections in humans as
the CVB group, but have been given a distinct classifica-
tion primarily because they lack pathogenicity in new-
born mice [5]. There are, however, strains of ECV that
are pathogenic in mice [6]. The prototype strain of ECV
18, Metcalf, was isolated in 1995 from a patient with
diarrhea in a sporadic case [7]. Thereafter, ECV18 was
isolated from patients with exanthematous febrile dis-
ease and aseptic meningitis [8,9]. Generally, the clinical
symptoms of HEVs, except for EV71, are asymptomatic
or mild, usually with non-specific symptoms such as
fever, irritation, agitation, sore throat, headache, myalgia,
vomiting, mild abdominal discomfort, and diarrhea [10].
But, a fatality due to ECV 18 infection was described
[11]. Recently, outbreaks of aseptic meningitis caused by
ECV 18 have been frequently reported [12-15]. From
1970-2005, two peaks of ECV18 activity were observed
in the United States (1986-1987 and 1995-2005), with
the mortality rate being around 1.8% from 1983 to 2005
[16,17]. An outbreak of aseptic meningitis caused by
ECV 18 occurred in Korea in 2005, marking the first
time that ECV 18 had been identified in the country
since enterovirus surveillance began in 1993 [18].
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The HEV genome containing ECV 18 consists of an
approximately 7,400 nucleotide (nt)-long single-stranded
polar RNA molecule that is attached to a viral peptide
(VPg) at the 5’ end. The length of the 5’ untranslated
region (UTR) in the genome is about 700 nt, which is
unusually long compared with the homologous region
of cellular mRNA. The 5’ UTR of HEVs harbors an
internal ribosomal entry site (IRES) that fold to adopt a
functional secondary RNA structure that drives transla-
tion initiation [19]. The coding region encompasses a
single open reading frame (ORF) that encodes a poly-
protein that can be divided into three sub-regions: P1,
P2, and P3. P1 encodes the genetic information of four
structural proteins: VP1-4. The non-structural proteins
are encoded in P2 (2A-2C) and P3 (3A-3D). A short 3’
UTR of approximately 100 nt separates the coding
region from the poly (A) tail [6,20].
Currently, approximately 40 antiviral agents have been
formally licensed for use in humans, mostly for treat-
ment of infections caused by human immunodeficiency
virus (HIV), hepatitis B virus (HBV), and herpes simplex
virus (HSV). The list of antiviral agents licensed for use
in treating highly-pathogenic RNA virus infections is
very short, and includes anti-influenza medications, M2
channel inhibitors (amantadine and rimantadine), and
neuramidase inhibitors (oseltamivir and zanaminir).
Mechanism of azidothymidine and lamivudine as anti-
viral agent of HIV are termination of reverse transcrip-
tion and viral DNA polymerase reaction, and acyclovir
for HSV and varicella zoster virus acts as a termination
of viral DNA polymerase reaction [21]. Ribavirin is
licensed for the treatment of respiratory syncytial virus
and hepatitis C virus infections [21,22]. Pleconaril was
developed in 1996 for treatment of diseases associated
with picornavirus infections and can be used in treat-
ments against enterovirus and rhinovirus infections [23].
However, pleconaril use is extremely limited and devel-
opment of resistance has been documented [24,25].
Previously, we explored the genetic diversity and anti-
viral activity for five common antiviral agents to ECV 5
isolated in Korea [26]. The present study extends these
observations to a Korean ECV 18 isolate. Recently, out-
breaks of aseptic meningitis by ECV 18 have been fre-
quently reported, but information concerning the
complete genome sequence is limited including in the
GenBank database. In this study, the molecular biologi-
cal characteristics and genetic diversity of Korean ECV
18, which is widespread and for which no antiviral
agents are known, were analyzed through complete
nucleotide sequencing and comparison with the Metcalf
prototype ECV 18 strain. Five compounds capable of
inhibiting viral reproduction (azidothymidine, acyclovir,
amantadine, lamivudine, and ribavirin) were tested for
antiviral activity for Korean ECV 18.
Materials and methods
Virus isolation and identification
The Korean ECV 18 strain was isolated from a stool
sample of a male patient with aseptic meningitis who
had been hospitalized to the Department of Pediatrics at
Soonchunhyang University Cheonan Hospital in April
2005. The pretreated specimen was inoculated into Vero
cells and incubated at 37°C in an atmosphere of 5%
CO2 until the appearance of cytopathic effects (CPE).
The identification of the Korean isolate was verified by a
Basic Local Alignment Search Tool search of VP1
sequences at the National Center for Biotechnology
Information website http://www.ncbi.nlm.nih.gov/. The
VP1 sequences of Korean isolate had the highest nucleo-
tide similarity with ECV 18 serotype strains [3].
Nucleotide sequencing and sequence analysis
The complete nucleotide sequence of the Korean ECV
18 strain was determined using a primer walking strat-
egy; the sequences of the genome termini were deter-
mined by random amplification of cDNA ends (RACE)
system (Invitrogen, Carlsbad, CA, USA). Polymerase
chain reaction (PCR) products were purified using a
QIAquick PCR Purification Kit (Qiagen, Valencia, CA,
USA). The purified DNA was added to a reaction mix-
ture containing 2 μL of terminator reaction mix (ABI
Prism BigDye Terminator Cycle Sequencing Kit; Applied
Biosystems, Foster, CA, USA) and 2 pmole of each pri-
mer. Sequencing involved an initial denaturation at 96°C
for 1 min and 25 cycles consisting of 96°C for 10 sec,
50°C for 5 sec, and 60°C for 4 min in a Gene Amp PCR
system 2700 (Applied Biosystems). The products were
purified by precipitation with 100% cold ethanol and 3
M sodium-acetate (pH 5.8), then loaded on an auto-
mated 3100 Genetic Analyzer (Applied Biosystems).
Nucleotide sequences of ECV 18 Korean isolates were
constructed to contig and were compared with the
reference Metcalf strain (Accession no. AF317694). The
Metcalf nucleotide sequence was obtained from the
GenBank database [27]. Sequence analyses were per-
formed using computer software included in the Laser-
gene package (DNASTAR, Madison, WI, USA).
Antiviral drugs and antiviral activity assays
Assays of antiviral activity and cytotoxicity involved the
modified sulforhodamine B (SRB) assay [28-30]. Riba-
virin was purchased from DUCHEFA (Haarlen, Nether-
lands). Azidothymidine, acyclovir, amantadine,
lamivudine, and sulforhodamine B (SRB) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA).
One day before infection, Vero cells were seeded (2 ×
104 cells/well) in wells of a 96-well plate. The next day,
the medium was removed from each well and the adher-
ent cells were washed with 1 × phosphate buffered
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saline (PBS). Infectivity of the virus stock was deter-
mined by the SRB assay [28-30] and was determined as
infectivity of the ECV 18 by SRB ID50 (50% infective
dose). Subsequently, 0.09 mL of diluted virus suspension
of ECV 18 containing CCID50 (50% cell culture infective
dose) of the virus stock to produce an appropriate CPE
within 2 days after infection and 0.01 mL of medium
containing an appropriate concentration of the com-
pounds were added. The antiviral activity of each agent
was determined with a 10-fold diluted concentration
ranging from 0.1-100 μg/mL. Three wells were used as
ECV 18 controls (virus-infected non-drug-treated cells),
while three wells were used as cell controls (non-
infected, non-drug-treated cells). The culture plates
were incubated at 37°C in 5% CO2 for 2 days. After
washing once with 1 × PBS, 100 μL of cold (-20oC),
70% acetone was added to each well and left for 30 min
at -20oC. The acetone (70%) was discarded and each 96-
well plate was dried in an oven for 30 min. 100 μL of
0.4% (w/v) SRB in 1% acetic acid was added to each
well and left at room temperature for 30 min. Unbound
SRB was removed and the plates were washed five times
with 1% acetic acid before oven-drying prior to being
left in the drying oven for one day. Bound SRB was
solubilized with 100 μL of 10 mM unbuffered Tris-base
solution and each plate was left on a table for 30 min.
The absorbance was read at 540 nm using a VERSAmax
microplate reader (Molecular Devices, Palo Alto, CA,
USA) with a reference absorbance at 620 nm. To calcu-
late the IC50 (50% inhibitory concentration) values, the
results were transformed to percentage of controls and
the IC50 values were graphically obtained from the dose-
response curves. The percent protection achieved by the
test compound in ECV 18-infected cells was calculated




where (ODt)ECV 18 is the optical density measured
with a given concentration of the test compound in
ECV 18-infected cells, (ODc)ECV 18 is the optical density
measured for the control untreated ECV 18-infected
cells, and (ODc)mock is the optical density measured for
control untreated mock-infected cells. The therapeutic
index was defined as 50% cytotoxic concentration
(CC50)/IC50.
Cytotoxicity assay
Vero cells were seeded into wells of a 96-well culture
plate at a concentration of 2 × 104 cells/well. The next
day, the medium was discarded and the medium in each
well was replaced with medium containing the serially-
diluted drugs, and the cells were incubated for another
48 hours. The culture medium was removed and the
adherent cells were washed with 1 × PBS. The next step
assessed antiviral activity as described above. To calcu-
late the CC50 values, the results were transformed to
percentage of controls and the CC50 values were graphi-
cally obtained from the dose-response curves.
Results
Complete nucleotide sequence of Korean ECV18
The genome of the Korean ECV 18 isolate was sequenced
(GenBank accession no. HM777023) and its amino acid
sequence was deduced. The genome was 7,413 nt in
length, excluding the poly(A) tail. The 5’ UTR contained
743 nt, followed by an ORF that encoded a viral polypro-
tein consisting of 2,189 codons, between a start codon
(AUG) at position 744 and a stop codon (UGA) at posi-
tion 7,310. The 3’ UTR was 103 nt in length.
Genome comparison between the Korean ECV18 isolate
and the Metcalf strain
The Korean ECV 18 isolate genome was divided into
five regions (5’ UTR, P1, P2, P3, and 3’ UTR) and
Table 1 Comparison of identities in nucleotide and
amino acid sequence between the Korea ECV 5 and 18
isolates with each prototype strain
5’UTR P1 P2 P3 3’UTR
ECV 5* Nucleotide 81.8 85.3 80.0 84.8 84.5
Amino Acid - 97.7 96.9 98.0 -
ECV 18 Nucleotide 82.0 79.7 81.2 82.2 94.2
Amino Acid - 95.2 96.9 96.8 -
* The results of ECV 5 were reported by Park et al. [26].
ECV5 and ECV18 are compared with Noyce and Metcalf strains, respectively.
Table 2 Comparison of predicted N-terminal cleavage
sites for the Korean ECV 5 and 18 isolate with each
prototype strain
Region ECV 5* ECV 18
Noyce Kor-ECV5 Metcalf Kor-ECV18
P1 VP4 - - - -
VP2 LN/SP LN/SP LN/SP LN/SP
VP3 PQ/GL PQ/GL TQ/GV TQ/GV
VP1 LQ/GD LQ/GD LQ/GD LQ/GD
P2 2A TY/GA TR/GA TH/GA TH/GA
2B EQ/GV EQ/GV EQ/GV EQ/GV
2C RQ/NN RQ/NN RQ/NN RQ/NS
P3 3A FQ/GP FQ/GP FQ/GP FQ/GP
3B FQ/GA FQ/GA FQ/GA FQ/GA
3C VQ/GP VQ/GP VQ/GP VQ/GP
3D EQ/GE EQ/GE EQ/GE EQ/GE
* The results of ECV 5 were reported by Park et al. [26].
ECV5 and ECV18 are compared with Noyce and Metcalf strains, respectively.
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aligned with the Metcalf strain using Megalign. The 3’
UTR region had the highest level of nucleotide identity
(85.3%), followed by the P3 region (82.2%), 5’ UTR
(82.0%), P2 (81.2%), and the P1 region (79.7%). The P2
region displayed the highest level of amino acid iden-
tity (96.9%), followed by the P3 region (96.8%), and the
P1 region (95.2%) (Table 1). Most of the cleavage sites
were identical between the Korean ECV 18 isolate and
the Metcalf strain. The only exception was the cleavage
site between 2B and 2C, which was RQ/NN in the
Metcalf strain and RQ/NS in the Korean ECV 18 iso-
late (Table 2).
Antiviral activity of Korea ECV18
No signs of cytotoxicity were observed in Vero cells trea-
ted with any of the five antiviral agents at a CC50 value
>100 μg/mL. Amantadine and ribavirin exhibited antiviral
activity against the Korean ECV 18 strain, while azidothy-
midine, acyclovir, and lamivudine did not. Amantadine
displayed an IC50 value of 4.97 ± 0.77 μg/mL and a TI
value of 20.12, while ribavirin displayed an IC50 value of
7.63 ± 0.87 μg/mL and a TI value of 13.11 (Table 3 and
Figure 1).
Discussion
This is the first report that describes the complete
nucleotide sequence for an ECV 18 isolated in Korea. A
previous study demonstrated a relatively high sequence
identity between different ECV serotypes for the 5’UTR
sequence, moderate for the P2 and P3 regions, and low-
est for the P1 region [31]. However, this pattern was dif-
ferent from the comparison between the Korean ECV 18
isolate and the Metcalf strain, in which the 3’UTR had
the highest nucleotide sequence identity (94.2%), while
the identities of the other regions were relatively low
(>82.2%). Amino acid sequences for the functional pro-
tein coding regions had much higher sequence identities
(>96.8%).
Generally, it has reported that about a 20% genetic
difference between the Metcalf prototype and the cur-
rent widespread strain exists, mainly at the cleavage site.
Therefore, development and screening of antiviral drugs
have to be focused on the object of the current epidemic
strain [28]. Cleavage site variations have often been
reported for VP2/VP3, VP3/VP1, and VP1/2A [31,32].
However, presently a substitution (RQ/NN®RQ/NS) at
2B/2C in ECV 18 was observed. Cleavage site variations
between ECV 5 and ECV 18 were evident in P1 of the
capsid protein coding region, rather than P2 and P3 of
non-structural protein coding regions.
Of the five antiviral drugs presently-tested (azidothy-
midine, acyclovir, amantadine, lamivudine, and riba-
virin), only amantadine (IC50: 4.97 μg/mL) and ribavirin




Azidothymidine NDd >100 -
Acyclovir NDd >100 -
Amantadine 4.97 ± 0.77 >100 20.12
Lamivudine NDd >100 -
Ribavirin 7.63 ± 0.87 >100 13.11
These results represent mean ± S.D (n = 3).
a Concentration of compound in μg/mL producing 50% inhibition of virus-
induced cytopathic effects.
b The 50% cytotoxic concentration for target cells in μg/mL.
C Therapeutic index (TI) = CC50/IC50
d Not Determined
Figure 1 Efficacy of antiviral agents at preventing cytopathic effects of Vero cells induced by infection with Korean ECV 18. The
concentration of each drug is commonly 100 μg/mL, and time of reaction is 72 hours.
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(IC50: 7.63 μg/mL) displayed antiviral activity against
Korean ECV 18, with amantadine showing stronger
effects than ribavirin. The same results were obtained
with the ECV 5 antiviral activity test. Therefore, amanta-
dine and ribavirin could be applied to patients infected
with ECV 18 as well as ECV 5 infection. Amantadine
suppresses the IRES mediated translation and ribavirin
is a nucleoside analogue with broad-spectrum antiviral
activity by decreasing viral replication in EV71 [33,34].
In conclusion, this manuscript is the first report of the
complete nucleotide sequence of the Korean ECV 18
strain, as well as the first examination of its response to
various antiviral agents. This data should be useful in
preventing future outbreaks of ECV 18 and in treating
patients infected with the strain. Accordingly, it is
necessary to screen the activities of the same kind of
antiviral agents to the various enterovirus serotypes and
reveal the antiviral mechanisms.
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